SHATTUCK LABS INC (STTK) Stock Price, Forecast & Analysis
NASDAQ:STTK • US82024L1035
STTK Key Statistics, Chart & Performance
The current stock price of STTK is 3.995 USD. In the past month the price decreased by -13.79%. In the past year, price increased by 191.97%.
STTK Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to STTK. When comparing the yearly performance of all stocks, STTK is one of the better performing stocks in the market, outperforming 98.37% of all stocks.
STTK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to STTK. STTK has a great financial health rating, but its profitability evaluates not so good.
STTK Financial Highlights
Over the last trailing twelve months STTK reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 33.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.03% | ||
| ROE | -59.22% | ||
| Debt/Equity | 0 |
STTK Forecast & Estimates
13 analysts have analysed STTK and the average price target is 7.4 USD. This implies a price increase of 85.11% is expected in the next year compared to the current price of 3.995.
For the next year, analysts expect an EPS growth of 47.46% and a revenue growth -82.07% for STTK
STTK Ownership
STTK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 411.552B | ||
| AMGN | AMGEN INC | 16.78 | 201.047B | ||
| GILD | GILEAD SCIENCES INC | 17.11 | 192.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.16 | 121.106B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.02 | 83.892B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.47 | 43.941B | ||
| INSM | INSMED INC | N/A | 32.101B | ||
| NTRA | NATERA INC | N/A | 29.393B | ||
| BIIB | BIOGEN INC | 12.76 | 28.709B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.05 | 20.773B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About STTK
Company Profile
Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. The company is headquartered in Austin, Texas and currently employs 44 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The firm is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. The company is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Company Info
SHATTUCK LABS INC
500 W. 5Th Street, Suite 100
Austin TEXAS 78703 US
CEO: Taylor Schreiber
Employees: 44
Phone: 18003166660
SHATTUCK LABS INC / STTK FAQ
What does STTK do?
Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. The company is headquartered in Austin, Texas and currently employs 44 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The firm is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. The company is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Can you provide the latest stock price for SHATTUCK LABS INC?
The current stock price of STTK is 3.995 USD. The price decreased by -0.12% in the last trading session.
What is the dividend status of SHATTUCK LABS INC?
STTK does not pay a dividend.
What is the ChartMill rating of SHATTUCK LABS INC stock?
STTK has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for SHATTUCK LABS INC?
The Revenue of SHATTUCK LABS INC (STTK) is expected to decline by -82.07% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for SHATTUCK LABS INC?
SHATTUCK LABS INC (STTK) will report earnings on 2026-03-25, after the market close.